POLB — Poolbeg Pharma Share News
0.000.00%
Last trade - 00:00Interim Results for the six months to 30 June 2026
POLB 001 TOPICAL trial recruitment update
Interim data from POLB 001 TOPICAL clinical trial
Notification of Major Holdings
Key Conference Participation in September 2026
Notification of major holdings
Notification of Major Holdings
AIM - AIM Notice - 21/07/2026
Notice of Allowance for POLB 001 patent in Israel
UK-listed Poolbeg Pharma slides after equity placement priced at 16% discount
Brief: Poolbeg Pharma Raises £3.5 Mln Via Placing Of 58.33 Million New Shares At 6 Pence/Share
Placing to raise £3.5 million
First patient dosed in POLB 001 TOPICAL trial
POLB 001 patent granted in South Africa
Brief: Poolbeg Pharma Says European Patent Granted For POLB 001 In CRS
PDMR Notification
Brief: Poolbeg Pharma Says FDA Feedback Broadly Aligned With Development Pathway For POLB 001
Brief: Poolbeg Pharma Announces Granted POLB 001 Cancer Immunotherapy-Induced CRS Patent In Canada
Annual Report & AGM Notice